Medivir presents at the Rodman & Renshaw Conference

Medivir has participated in, and was yesterday presented before, the Rodman & Renshaw Annual Global Investment Conference in New York, USA. The presentation is now available on our website:, under the IR&Media/Latest Events tab. For additional information, please contact Rein Piir, CFO & VP Investor Relations, Medivir +46 708 53 72 92. For more on Medivir, please see the company website:


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links